PubMed · 2016 · 18 citations · 0 references
MedicineImmunologyOncologyAdaptive ImmunityCancer ImmunologyImmunotherapyAntitumor T Cell ResponsesAutophagy In ImmunityCancer ImmunotherapyCancer VaccinesCell-mediated ImmunityImmunotherapy For Brain TumorsAdaptive Immune Response PrimingAntigen Presenting CellsGlioblastoma Drug TherapyGlioblastoma ImmunologyGlioblastoma ImmunotherapyGlioma ChemotherapyTemozolomide TherapyValproic Acid
BACKGROUND/AIM: The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown. MATERIALS AND METHODS: We investigated the in vitro and in vivo effects of pretreating glioma cells with temozolomide and VPA as an immunization strategy to boost an adaptive immune response in a syngeneic mouse model. RESULTS: Temozolomide and VPA induced autophagy in GL261 glioma cells, and caused tumor antigen-specific T-cells to become activated effector T-cells. Mice with a pre-existing glioma showed no improvement in clinical outcome when immunized with temozolomide- and VPA-treated glioma cells. CONCLUSION: Although temozolomide and VPA treatment of glioma cells can boost the adaptive immune response, in the context of a vaccine therapy, additional factors are necessary to eradicate the tumor and improve survival.